Kailera Therapeutics
↗Waltham, MA, USA
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing a broad, advanced, and differentiated portfolio of injectable and oral therapies for the treatment of obesity and related metabolic conditions. The company's pipeline leverages multiple incretin-based mechanisms, including GLP-1/GIP dual agonists and other novel approaches, to provide diverse treatment options for chronic weight management.
Launched in October 2024 with significant venture backing, Kailera operates with a strategic focus on global development. The company holds exclusive rights outside of Greater China to a portfolio of metabolic assets licensed from Jiangsu Hengrui Pharmaceuticals, which have already generated clinical data packages in China. Kailera is actively advancing these programs through global clinical trials, including late-stage studies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$20M
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$1000M
Investors:Bain Capital Life Sciences, Atlas Venture, RTW Investments, Lyra Capital, Canada Pension Plan Investment Board, T. Rowe Price, Qatar Investment Authority
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Peptide, GLP-1/GIP dual agonist
Active Trials:1
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Jiangsu Hengrui Pharmaceuticals (Licensing agreement for four metabolic assets)
COMPETITION
Position:Emerging
Competitors:Eli Lilly, Novo Nordisk
LEADERSHIP
Key Executives:
Ron Renaud - CEO
LINKS
Website:kailera.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Kailera Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kailera Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.